ATH Share Price Performance
AU$0.014
0.01 (366.67%)
Price AU$0.014
Share PriceAU$0.014
ATH Community Narratives
There are no narratives available yet.
Recent ATH News & Updates
No updates
Alterity Therapeutics Limited Key Details
Last Reported Earnings
Dec 31, 2024
Next Reporting Earnings
n/a
- Earnings per share (EPS)
- -0.0021
- Gross Margin
- 95.14%
- Net Profit Margin
- -531.34%
- Debt/Equity Ratio
- 0%
Alterity Therapeutics Limited Competitors
About ATH
- Founded
- 1997
- Employees
- 10
- CEO
- WebsiteView website
Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer’s disease, Huntington disease, Parkinson’s disease, and other neurological disorders in Australia. The company’s lead drug candidate is ATH434, a small molecule drug candidate that has completed Phase I clinical trial for the treatment of Parkinson’s disease. It is also developing ATH434-201, which is in Phase II clinical trial to treat multiple system atrophy early stage; ATH434-202 that is in Phase II clinical trial to treat multiple system atrophy; and PBT2 that has completed Phase 2a clinical trial to treat Alzheimer’s disease. The company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limited in April 2019. Alterity Therapeutics Limited was incorporated in 1997 and is headquartered in Melbourne, Australia.
Australian Market Performance
- 7 Days: -0.4%
- 3 Months: 6.8%
- 1 Year: 13.2%
- Year to Date: 5.2%
Over the last 7 days, the market has remained flat, with no particular sector making any big moves this week. As for the longer term, the market has risen 13% in the past 12 months. Earnings are forecast to grow by 11% annually. Market details ›
This week, we’re diving deeper into the world of agentic AI. We’re zeroing in on the core technologies that make these intelligent agents actually reliably work. We explore what all this could mean for software, start-ups, and most importantly, the opportunities and risks each industry faces by adopting Agentic AI.
Continue reading